The proposal has significance in that it would establish the scientific capability, the administrative expertise and essential physical equipment for: 1. On-going pharmacologic study of established, effective oncologic drugs used in treating malignancies of childhood permitting: a. Rational rather than empirical dosage schedules, b. better understanding of toxicity and its prevention, c. comparison of pharmacokinetics in children with published data for adults with a view to determining age related differences, and d. monitoring for compliance to permit better evaluation of individuals, as well as groups of patients, to give the physician an opportunity to secure better compliance should it be lacking. 2. Pharmacologic evaluation of new formulations of drugs used in treating cancer in children. The actual research projected centers around the expertise of Dr. Nelson in applying methodology of cancer drugs to research and cancer problems.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-16
Application #
3101602
Study Section
Special Emphasis Panel (SRC (15))
Project Start
1978-07-01
Project End
1992-06-30
Budget Start
1990-07-23
Budget End
1991-06-30
Support Year
16
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Qian, Xu; Li, Xinjian; Tan, Lin et al. (2018) Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress. Cancer Discov 8:94-107
Dashti, S Ghazaleh; Win, Aung Ko; Hardikar, Sheetal S et al. (2018) Physical activity and the risk of colorectal cancer in Lynch syndrome. Int J Cancer 143:2250-2260
Livingston, J Andrew; Wang, Wei-Lien; Tsai, Jen-Wei et al. (2018) Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Mol Cancer Ther 17:1315-1323
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707
Vijayaraghavan, Smruthi; Moulder, Stacy; Keyomarsi, Khandan et al. (2018) Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol 13:21-38
Tsai, Edward; Robertson, Michael C; Lyons, Elizabeth J et al. (2018) Physical activity and exercise self-regulation in cancer survivors: A qualitative study. Psychooncology 27:563-568
Rosenstock, Aron S; Niu, Jiangong; Giordano, Sharon H et al. (2018) Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer 124:899-906
Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua et al. (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173:321-337.e10
Fleming, Nicole D; Nick, Alpa M; Coleman, Robert L et al. (2018) Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol 132:545-554

Showing the most recent 10 out of 12418 publications